Critical issues on high-dose chemotherapy with autologous hematopoietic progenitor cell transplantation in breast cancer patients

Expert Opinion on Biological Therapy

Volumn 12, Issue 11, 2012, Pages 1505-1515

  Martino, Massimo ^a   Bottini, Alberto ^b   Rosti, Giovanni ^c   Generali, Daniele ^b   Secondino, Simona ^d   Barni, Sandro ^e   Maisano, Roberto ^a   Lanza, Francesco ^b   Castagna, Luca ^f   Pedrazzoli, Paolo ^d  

^a BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^b CREMONA HOSPITAL   (Italy)

^c OSPEDALE CA FONCELLO   (Italy)

^d FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^e TREVIGLIO HOSPITAL   (Italy)

^f HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Autologous hematopoietic progenitor cell transplantation; High dose chemotherapy; High risk breast cancer; Metastatic breast cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; METHOTREXATE; MITOXANTRONE; THIOTEPA;

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; DISEASE FREE SURVIVAL; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; HIGH DOSE CHEMOTHERAPY; HUMAN; LENGTH OF STAY; LEUKAPHERESIS; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; REVIEW; ANIMAL; AUTOTRANSPLANTATION; BREAST NEOPLASMS; DOSE RESPONSE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MORTALITY; MULTIMODALITY CANCER THERAPY; PROCEDURES; TRENDS;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRANSPLANTATION, AUTOLOGOUS;

EID: 84867285965     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.721767     Document Type: Review

References (87)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49
2. Breast Cancer Home Page - National Cancer Institute. Available from: http://www.cancer.gov/cancertopics/types/breast
3. Greenberg PA, Hortobagyi GN, Smith TL, et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J. Clin Oncol 1996;14:2197-05
4. Stockler M, Beith J. Youth and hormone receptors in breast cancer: good or bad news first? Lancet 2000;355:1839-40
5. Gennari A, Conte P, Rosso R, et al. Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer 2005;104:1742-50
6. Peters WP, Ross M, Vredenburgh JJ, et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993;11:1132-43
7. Gianni AM, Siena S, Bregni M, et al. Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results. J Clin Oncol 1997;15:2312-21
8. Pedrazzoli P, Rosti G, Secondino S, et al. High-dose chemotherapy with autologous hematopoietic stem cell support for solid tumors in adults. Semin Hematol 2007;44:286-95
9. Siena S, Schiavo R, Pedrazzoli P, et al. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 2000;18:1360-77
10. Weiss RB, Rifkin RM, Stewart FM, et al. High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study. Lancet 2000;355:999-03
11. Nitz UA, Mohrmann S, Fischer J, et al. Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre Phase III trial. Lancet 2005;366:1935-44
12. Rodenhuis S, Bontenbal M, van Hoesel QG, et al. Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer. Ann. Oncol 2006;17:588-96
13. Berry DA, Ueno NT, Johnson MM, et al. High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. J Clin Oncol 2011;29:3214-23
14. Berry DA, Ueno NT, Johnson MM, et al. High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: overview of six randomized trials. J Clin Oncol 2011;29:3224-31
15. De Giorgi U, Amadori D. Dose intensification in hormone receptor-negative and/or human epidermal growth factor receptor 2-negative high-risk primary breast cancer. J Clin Oncol 2012;30:758
16. Wang J, Zhang Q, Zhou R, et al. High-dose chemotherapy followed by autologous stem cell transplantation as a first-line therapy for high-risk primary breast cancer: a meta-analysis. PLoS One. 2012;7(3):e33388
17. Pedrazzoli P, Ferrante P, Kulekci A, et al. Autologous hematopoietic stem cell transplantation for breast cancer in Europe: critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) Registry. 1990-1999. Bone Marrow Transplant 2003;32:489-94
18. Eder J, Antman K, Peters W, et al. High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. J Clin Oncol 1986;4:1592-7
19. Hortobagyi GN, Buzdar AU, Theriault RL, et al. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst 2000;92:225-33
20. Rodenhuis S, Richel DJ, van der Wall E, et al. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet 1998;352:515-21
21. Tallman MS, Gray R, Robert NJ, et al. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med 2003;349:17-26
22. Peters WP, Rosner GL, Vredenburgh JJ, et al. Prospective, randomized comparison of high dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high risk primary breast cancer: A report of CALGB 9082, SWOG 9114, and NCIC MA-13. J Clin Oncol 2005;23:2191-200
23. Gianni A, Bonadonna G. Michelangelo Cooperative Group. Five-year results of the randomized clinical trial comparing standard versus high-dose myeloablative chemotherapy in the adjuvant treatment of breast cancer with > 3 positive nodes (LN). (abstract 80). Proc Am Soc Clin Oncol 2001;20:21a
24. Zander AR, Kroger N, Schmoor C, et al. High dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial. J Clin Oncol 2004;22:2273-83
25. Coombes RC, Howell A, Emson M, et al. High dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: long-term results of an international randomized trial. Ann Oncol 2005;16:726-34
26. Tokuda Y, Tajima T, Narabayashi M, et al. Phase III study to evaluate the use of high-dose chemotherapy as consolidation of treatment for high-risk postoperative breast cancer: japan Clinical Oncology Group study, JCOG 9208. Cancer Sci 2008;99:145-51
27. Bergh J, Wiklund T, Erikstein B, et al. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breastcancer: A randomised trial-Scandinavian Breast Group 9401 study. Lancet 2000;356:1384-91. Erratum in: Lancet 356:2196
28. Roche H, Viens P, Biron P, et al. High-dose chemotherapy for breast cancer: the French PEGASE experience. Cancer Contr 2003;10:42-7
29. Leonard RC, Lind M, Twelves C. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial. J Natl Cancer Inst 2004;96:1076-83
30. International Breast Cancer StudyGroup. Basser RL, O'Neill A, et al. Multi cycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study group Trial 15-95. J Clin Oncol 2006;24:370-8
31. Moore HC, Green SJ, Gralow JR, et al. Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: southwest Oncology group/IntergroupStudy 9623. J Clin Oncol 2007;25:1677-82
32. Stadtmauer EA, O'Neill A, Goldstein LJ, et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer: philadelphia Bone Marrow Transplant Group. N Engl J Med 2000;342:1069-76
33. Crown JP, Leyvraz S, Verrill M, et al. High dose chemotherapy (HDC) produces a superior rate of durable complete remission (DCR) compared to conventional chemotherapy in metastatic breast cancer (MBC): Mature results of the International Breast Cancer Dose-Intensity Study (abstract 1020). Ann Oncol 2004;15(Suppl 3):iii27
34. Schmid P, Schippinger W, Nitsch T, et al. Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial. J. Clin. Oncol 2005;23:432-40
35. Lotz JP, Cure H, Janvier M, et al. High-dose chemotherapy with haematopoietic stem cell transplantation for metastatic breast cancer patients: final results of the French multicentric randomised CMA/PEGASE 04 protocol. Eur J Cancer 2005;41:71-80
36. Vredenburgh JJ, Coniglio D, Broadwater G, et al. Consolidation with high-dose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compared with intensive standard dose chemotherapy alone. Biol. Blood Marrow Transplant 2006;12:195-203
37. Vredenburgh JJ, Madan B, Coniglio D, et al. A randomized Phase III comparative trial of immediate consolidation with high-dose chemotherapy and autologous peripheral blood progenitor cell support compared to observation with delayed consolidation in women with metastatic breast cancer and only bone metastases following intensive induction chemotherapy. Bone Marrow Transplant 2006;37:1009-15
38. Biron P, Durand M, Roche H, et al. Pegase 03: a prospective randomized Phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer. Bone Marrow Transplant 2008;41:555-62
39. Crump M, Gluck S, Tu D, et al. Randomized trial of high-dose chemotherapy with autologous peripheral blood stem cell support compared with standard chemotherapy in women with metastatic breast cancer: NCIC MA.16. J Clin Oncol 2008;26:37-43
40. Stadtmauer EA, O'Neill L, Goldstein LJ, et al. Conventional-dose chemotherapy compared with high-dose chemotherapy (HDC) plus autologous stem cell transplantation (SCT) for metastatic breast cancer: 5 year update of the 'Philadelphia Trial' (PBT-01). Proc Am Soc Clin Oncol 2002;21:abstract 43
41. Baldomero H, Gratwohl M, Gratwohl A, et al. The EBMT activity survey 2009: trends over the past 5 years. Bone Marrow Transplant 2011;46:485-01
42. Korbling M, Fliedner TM. The evolution of clinical peripheral blood stem cell transplantation. Bone Marrow Transplant 1996;17:675-8
43. Siena S, Bregni M, Di Nicola M, et al. Durability of hematopoiesis following autografting with peripheral blood hematopoietic progenitors. Ann Oncol 1994;5:935-41
44. Yanovich S, Mitsky P, Cornetta K, et al. Transplantation of CD34+ peripheral blood cells selected using a fully automated immunomagnetic system in patients with high-risk breast cancer: results of a prospective randomized multicenter clinical trial. Bone Marrow Transplant 2000;25:1165-17
45. Marino P, Roche H, Moatti JP, et al. High-dose chemotherapy for patients with high-risk breast cancer: a clinical and economic assessment using a quality-adjusted survival analysis. Am J Clin Oncol 2008;31:117-24
46. Antman KH, Rowlings PA, Vaughan WP, et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 1997;15(5):1870-9
47. Moroni M. High-Dose chemotherapy as adjuvant therapy in breast cancer: could there be a survival benefit? J Clin Oncol 2012;30:759
48. Berry DA, Moroni M, De Giorgi U, et al. Dose intensification in hormone receptor-negative and/or human epidermal growth factor receptor 2-negative high-risk primary breast cancer. J Clin Oncol 2012;30:759-60
49. Bonadonna G, Valagussa P, Moliterni A, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995;332:901-6
50. Hryniuk W, Frei E III, Wright FA. A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: summation dose intensity. J Clin Oncol 1988;16:3137-47
51. Hortobagyi GN. What is the role of high-dose chemotherapy in the era of targeted therapies? J Clin Oncol 2004;22:2263-6
52. Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005;352:2302-13
53. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;2:976-83
54. Burstein HJ. Avastin for breast cancer, 2005-2011: requiescat in pacem? J Natl Compr Canc Netw 2011;1:1321-3
55. La Verde NM, Bramati A, Bianchi A, et al. Efficacy of biologic agents (BA) in metastatic, triple-negative breast cancer (TNBC): a systematic review. J Clin Oncol 2011;15(Suppl):e11587
56. O'Shaughnessy J, Schwartzberg LS, Danso MA, et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J Clin Oncol 2011;29(15 Suppl):1007
57. Rajkumar SV, Gahrton G, Bergsagel PL. Approach to the treatment of multiple myeloma: a clash of philosophies. Blood 2011;118(12):3205-11
58. Leoncini O, Da Prada GA, Pedrazzoli P. Costs of autologous stem-cell transplantation in solid tumours. Ann Oncol 2001;12:131
59. Barosi G, Marchetti M, Alessandrino P, et al. A model for analysing the cost of autologous peripheral blood progenitor cell (PBPC) transplantation. Bone Marrow Transplant 1999;23:719-25
60. Sonnenberg FA, Beck J.R. Markov models in medical decision making: a practical guide. Med Dec Making 1993;13:322-38
61. Mishra V, Vaaler S, Brinch L. Cost analysis of autologous peripheral blood stem cell transplantation for multiple myeloma. Clin Lab Haematol 2003;25(3):179-84
62. Mishra V, Andresen S, Brinch L, et al. Cost of autologous peripheral blood stem cell transplantation: the Norwegian experience from a multicenter cost study. Bone Marrow Transplant 2005;35:1149-53
63. Ferrara F, Izzo T, Criscuolo C, et al. Comparison of fixed dose pegfilgrastim and daily filgrastim after autologous stem cell transplantation in patients with multiple myeloma autografted on a outpatient basis. Hematol Oncol 2011;29:139-43
64. Morabito F, Martino M, Stelitano C, et al. Feasibility of a mixed inpatient-outpatient model of peripheral blood stem cell transplantation for multiple myeloma. Haematologica 2002;87(11):1192-9
65. Meisenberg BR, Ferran K, Hollenbach K, et al. Reduced charges and costs associated with outpatient autologous stem cell transplantation. Bone Marrow Transplant 1998;21:927-32
66. Morabito F, Irrera G, Oliva E, et al. Infectious complications in breast cancer patients undergoing peripheral blood stem cell transplantation: a single center retrospective analysis towards outpatient strategy. Bone Marrow Transplant 2001;28(9):883-8
67. Elfenbein GJ. Stem-cell transplantation for high-risk breast cancer. N Engl J Med 2003;349(1):80-2
68. Sargent DJ, Wieand HS, Haller DG, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2005;23(34):8664-70
69. Andre T, Boni C, Mounedji-Boudiaf L. Oxaliplatin fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-51
70. Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13(1):25-32
71. Chan A, Miles DW, Pivot X. Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer. Ann Oncol 2010;21:2305-15
72. Baselga J, Cortes J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012;366(2):109-19
73. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34
74. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359(17):1757-65
75. Gluz O, Mengele K, Schmitt M, et al. Y-box-binding protein YB-1 identifies high-risk patients with primary breast cancer benefiting from rapidly cycled tandem high-dose adjuvant chemotherapy. J Clin Oncol 2009;27:6144-51
76. Diallo-Danebrock R, Ting E, Gluz O, et al. Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose-dense chemotherapy. Clin Cancer Res 2007;13:488-97
77. Nieto Y, Shpall EJ. High-dose chemotherapy for high-risk primary and metastatic breast cancer: is another look warranted? Curr Opin Oncol 2009;21(2):150-7
78. Bonilla L, Ben-Aharon I, Vidal L, et al. Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials. J Natl Cancer Inst 2010;102:1845-54
79. Nieto Y, Nawaz S, Jones RB, et al. Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer. J Clin Oncol 2002;20(3):707-18
80. Kurian S, Qazilbash M, Fay J, et al. Complete response after high-dose chemotherapy and autologous hemopoietic stem cell transplatation in metastatic breast cancer results in survival benefit. Breast J 2006;12:531-5
81. Martino M, Ballestrero A, Zambelli A, et al. Long-term survival in patients with metastatic breast cancer receiving intensified chemorherapy and stem cell rescue: data from the Italian registry. Bone Marrow Transplant 2012; doi: 10.1038/bmt.2012.149
82. Crown J, Wassherheit C, Hakes T, et al. Rapid delivery of multiple high-dose chemotherapy courses with granulocyte colony-stimulating factor and peripheral blood-derived hematopoietic progenitor cells. J Natl Cancer Inst 1992;84:1935-6
83. Moebus V, Jackisch C, Lueck HJ, et al. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol 2010;28:2874-80
84. Crown JP, Leyvraz S, Verrill M, et al. Effect of tandem high-dose chemotherapy (HDC) on long-term complete remissions (LTCR) in metastatic breast cancer (MBC), compared to conventional dose (CDC) in patients (pts) who were not selected on the basis of response to prior CT: mature results of the IBDIS-I [abstract 631]. In: Grunberg SM, editor. Proceedings of the 40th Annual Meeting of the American Society of Clinical Oncology, 2004
85. Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003;349:2495-502
86. Simonelli M, Rosti G, Banna GL, Pedrazzoli P. On behalf of the Italian Germ cell cancer Group (IGG) and Gruppo Italiano Trapianto Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare (GITMO). Intensified chemotherapy with stem-cell rescue in germ-cell tumors. Ann Oncol 2011; Epub ahead of print
87. Pedrazzoli P, Gianni AM, Da Prada G, et al. Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell transplantation for breast cancer with > 9 positive nodes: 15-year results from the Italian registry. J Clin Oncol 2008;26(Suppl 20):abstract 592